Skin, Hair & Aesthetic

GHK-Cu FDA Status for Clinics
Regulatory Guidance & Legal Compliance for Licensed Practitioners

Skin, hair and aesthetic peptide protocols sit in a different clinical space from gut health or tissue repair. The target is chronic, age-related change in skin quality rather than inflammatory disease or acute injury, which alters the timeline, the outcome measures and the evidence a clinic can reasonably expect to find. This page documents where the substances most discussed in this category actually stand as of August 2026. One of them has an unusual regulatory position that turns entirely on route of administration, and that distinction is the most important thing on the page.

How We Work:

Phoenix Meds Inc. is a peptide sourcing coordinator for licensed clinics. We coordinate sourcing where a lawful pathway exists, provide regulatory documentation where it does not, and tell clinics plainly which is which. For the statutory framework, the criteria under sections 503A and 503B, research-use-only labelling, enforcement risk and our partner model, see how the compounding rules work. This page covers only what applies to the aesthetic category.

HOW WE SUPPORT CLINICS

Phoenix Meds Regulatory Support Model

Aesthetic sourcing questions rarely turn on whether a substance is approved. They turn on route of administration and on what is actually inside a branded blend. Our support in this category is built around those two problems.

Status Tracked by Route

GHK-Cu’s position differs by route, and FDA’s own list draws that line explicitly. We track topical and injectable separately, because a supplier quote that does not name the route leaves the central question open.

Blend Composition Review

KLOW, GLOW, FOY and similar preparations are trade names, not characterised substances. We work through the component list with you and check each ingredient separately, because that is the only way a blend can be assessed at all.

Statutory Criteria Applied per Component

The three conditions under section 503A, and the separate conditions under 503B, applied to each ingredient rather than to the product name. Every constituent substance has to be assessed on its own, alongside the requirements that apply to the finished preparation.

Enforcement Risk, Explained

Aesthetic practices sit in a different enforcement position from medical clinics: state boards, cosmetic advertising rules and medspa supervision requirements all apply on top of federal law. We set that out so your own counsel can assess it. We are not lawyers and this is not a legal opinion.

Pharmacy Partner Network

For substances with a lawful pathway, we run credential and documentation checks on pharmacy partners — state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities operating under CGMP requirements — and review them per product and per jurisdiction. No partner can supply what has no pathway, and we do not attempt to arrange it.

Monitoring, With a Date in the Diary

GHK-Cu is under evaluation, not settled. Its Category 1 status is discretionary and reporting indicates a further advisory committee review is expected. We track the nominations list, both Bulks Lists and Federal Register notices, and re-date this page when anything moves.

Critical Note for this Category

As of August 2026 there is no lawful compounding pathway under section 503A or 503B for injectable GHK-Cu, for Fountain of Youth, or for multi-peptide aesthetic blends such as KLOW and GLOW. We put that finding in writing before anything is arranged. No supplier we have seen has produced a basis for these preparations.. Clinics exploring these preparations should do so with qualified legal counsel.

Clinic Benefits

What an aesthetic practice actually gets from working with us on this category.

✓ The Route Question, Answered

A straight answer on whether a given form of GHK-Cu sits inside FDA’s enforcement discretion or outside it, with the list entry quoted rather than paraphrased.

✓ Blend Transparency

Help obtaining a written component list from a supplier, and an ingredient-by-ingredient assessment once you have it. No blend can be judged from its trade name.

✓ Cosmetic Claim Awareness

Aesthetic marketing carries advertising exposure that clinical practice does not. We flag where a protocol description crosses from what was studied into what is claimed.

✓ Documentation Support

Help building a compliance file that records what you verified, when, and against which source — the record that matters if anyone asks later.

✓ Supplier Vetting

For preparations with a lawful pathway, we vet suppliers on credentials and statutory authority. Where no pathway exists, no credential cures the problem, and we say so.

✓ Counsel Ready

The regulatory position organised so your attorney can assess it in an hour rather than rebuilding the research from scratch.

Aesthetic Practice and the Evidence It Works With

Aesthetic practitioners work toward measurable change in the appearance and properties of skin and hair rather than treatment of disease. That shapes the evidence framework: outcomes are gradual, partly subjective, and difficult to separate from ordinary variation without objective measurement over months.

Practitioners in dermatology, aesthetics and age-management medicine have explored peptide approaches on the strength of preclinical work on fibroblast activity and collagen synthesis. Those explorations sit within prescriber discretion and clinical judgment—which is a separate question from whether the material can lawfully be obtained at all.

Route of administration decides the answer here

For GHK-Cu, route of administration is material to FDA’s current treatment of the substance. Any supplier conversation that does not begin with the route is not answering the question you asked.

The Substances Discussed in This Category

What it is: Copper bound to the tripeptide glycyl-L-histidyl-L-lysine, with a long history of use in topical cosmetic products.

Research context: Preclinical work covers collagen synthesis, fibroblast activity and dermal matrix composition across several skin models, with proposed activity through TGF-β pathways. Human clinical evidence for aesthetic endpoints is limited, and the topical cosmetic record does not carry over to injection: route, dose and systemic exposure all differ. Published work describes mechanism. It does not establish aesthetic outcomes in humans for injected material.

Regulatory position: FDA sorts nominated bulk substances into three categories while it reviews them. Category 1 covers substances not identified as presenting significant safety risks, where FDA exercises enforcement discretion during review. Category 2 covers substances FDA has flagged for safety risks. Neither is the 503A Bulks List, which is the only list that permits compounding.

GHK-Cu left Category 1 in April 2026 when its nomination was withdrawn. A nominator clarified on 5 May that it wished to withdraw the injectable form only, and FDA’s nominations list, updated 14 May 2026, returned the substance to Category 1 with an explicit exclusion. The entry reads “GHK-Cu (except for injectable routes of administration).”

Category 1 is neither permission nor a pathway: it records that FDA is not acting while it evaluates, and that position can change. GHK-Cu does not appear on the 503A Bulks List.

Injectable GHK-Cu falls outside the Category 1 entry. It appears on neither the 503A nor the 503B Bulks List. On the sources we reviewed in August 2026 we did not identify an FDA-approved drug product containing it, or an applicable USP or NF monograph. We have not identified a basis on which it could lawfully be compounded. It is the form used in the blends described below.

What it is: A trade name, not a substance. Preparations sold under it are multi-peptide formulations for aesthetic use, and nothing standardises them, so composition can differ between suppliers and between lots.

Research context: No published human clinical evidence examines FOY as a formulation. The literature on individual component peptides describes mechanisms studied in preclinical models, and those findings do not transfer to a combination: a blend’s effects are not the sum of its components studied separately.

Regulatory position: FDA’s bulk-substance framework operates substance by substance, against specific nominated uses, so no FDA determination attaches to a product name. The analysis starts from the identity, route and intended use of each component, and any component that does not qualify has to be resolved before the finished preparation can be considered under that framework.

That puts the first step with the supplier: without a written component list, there is nothing to assess. Once the components are known, each is checked against the conditions under section 503A, and separately under 503B. Where aesthetic formulations of this type contain injectable GHK-Cu, BPC-157, TB-500 or KPV, we have not identified a basis on which any of those components could lawfully be compounded.

Named Multi-Peptide Blends: KLOW, GLOW and Similar Formulations

Blends circulate under trade names rather than substance names. KLOW is sold as a four-peptide combination of GHK-Cu, BPC-157, TB-500 and KPV. GLOW is sold as a three-peptide version of the same idea, without KPV.

The naming matters for a reason that is easy to miss. FDA’s framework operates one bulk substance at a time, against a specific nominated use, so no FDA determination attaches to a blend’s trade name. Because the name establishes nothing on its own, a supplier should be able to identify the formulation’s ingredients, the route, and the legal basis they rely on for compounding or supplying it.

The rule that governs every combination

Combining substances into one preparation does not remove the need to evaluate each constituent substance, and the finished formulation, under the applicable federal and state requirements. If a required component does not qualify under the framework being relied on, that has to be resolved before the finished formulation can be considered eligible under it. Combination does not average the components’ status and does not create a new one.

Component status as of August 2026

GHK-Cu. Category 1 applies to non-injectable routes only, as set out above. Since KLOW and GLOW are injectable preparations, the GHK-Cu in them falls outside even that enforcement discretion.

BPC-157, TB-500 and KPV. None appears on the 503A Bulks List or the 503B Bulks List. On the sources we reviewed in August 2026, we did not identify an FDA-approved drug product containing any of them as a component, or an applicable USP or NF monograph. All three were considered by the Pharmacy Compounding Advisory Committee on 23 July 2026. FDA’s briefing materials set out the agency’s evaluation and recommended against inclusion in each case; the committee’s votes went the other way by narrow margins, as reported by trade press covering the meeting. Those votes are advisory and did not change the federal compounding framework. No rulemaking has followed.

What that adds up to

Every component of KLOW and GLOW fails the statutory test, and the copper peptide fails it specifically because these are injectables. There is no lawful route under section 503A or 503B for a United States pharmacy or outsourcing facility to compound either blend, and we say so before an order rather than after.

One further point worth raising with any supplier. FDA assessed these substances against particular nominated uses: ulcerative colitis for BPC-157, wound healing for TB-500 and for KPV. Aesthetic and cosmetic use was not the question in front of the agency for any of them. A blend marketed for skin quality is therefore built from substances that were never evaluated for that purpose, and whose evaluations, on the uses actually considered, went against them.

Regulatory status current as of August 2026.

For the injectable preparations on this page, we have not identified any basis on which a pharmacy or outsourcing facility could compound them under sections 503A or 503B. Compounding from a bulk drug substance is permitted only when the applicable statutory and regulatory requirements are satisfied; based on the sources we reviewed, we have not identified such a pathway here. That is not the same as a ban: the absence of a compounding pathway does not mean these substances are federally scheduled or controlled, and separate federal and state requirements may still apply. Non-injectable GHK-Cu is a different case, and FDA Category 1 status does not itself constitute approval or authorization to compound.

The Current Evidence Position

The topical cosmetic literature on copper peptides is long-standing and reasonably substantial. That is not the same body of evidence as the one a clinic needs when considering an injected preparation, and the distinction gets lost more often than any other point in this category.

For injected GHK-Cu in aesthetic indications, and for multi-peptide blends of any composition, we have not identified a completed controlled trial establishing outcomes in humans. Registry records change, so check ClinicalTrials.gov directly rather than relying on any secondhand summary, including this one. This means that:

Safety of injected material at aesthetic dosing is not characterised in humans.
Effective dose ranges for cosmetic endpoints are not established by trial.
Candidate patients, contraindications and objective outcome measures are not defined.
Durability after a protocol ends is not documented.
For blends, no evidence addresses the combination at all — only its parts, separately, in preclinical models.

Licensed prescribers working in this space operate in a domain of clinical discretion rather than evidence-based protocol. The decision to use, dose and monitor remains the prescriber’s responsibility under the standard of care in their jurisdiction.

Why Clinics Have Explored Aesthetic Peptides

Despite the regulatory and evidence limitations set out above, these preparations have gained attention in aesthetic settings because:

The topical record creates an assumption. Copper peptides have a long cosmetic history, and that familiarity transfers to injection in practitioners’ minds more readily than the evidence supports.
Conventional options have ceilings. For some patients, standard dermatologic approaches reach limits of efficacy or tolerability, which is why mechanism-based alternatives attract interest.
Off-label prescribing is familiar territory. Practitioners are used to broad discretion in prescribing approved drugs off-label. That discretion does not extend to obtaining a substance no pharmacy may lawfully compound. The two questions are commonly, and incorrectly, treated as one.
Patient demand is real. Patients encounter these preparations in cosmetic and wellness media and ask about them directly.

None of the above is a recommendation to use these compounds. We decline to coordinate anything without a lawful pathway, and this page exists so a clinic can see the whole position and hand it to counsel before a supplier quotes a price.

Two Questions Specific to This Category

Our regulatory overview sets out the general supplier checks that apply to every peptide: statutory criteria, pharmacy credentials, research-use-only labelling and documentation. Two questions matter here that do not arise elsewhere.

Ask about the route before anything else

For GHK-Cu, the route decides the regulatory answer. A supplier quoting “GHK-Cu” without specifying the form is answering a different question from the one you asked. Enforcement discretion under Category 1 covers non-injectable routes only, and it is discretion rather than authorisation in either case. If a quote arrives for injectable material on the strength of Category 1 status, that is a misreading of a list entry which expressly excludes injection.

Get the component list for any blend, in writing

You cannot assess KLOW, GLOW, FOY or any proprietary formulation without knowing exactly what is in it and at what strength. There is no FDA determination about a blend to fall back on, so the components are the only basis for an answer. A supplier unwilling to put the composition in writing has answered the only question that matters.

Availability Through Phoenix Meds

Product Availability Notice (August 2026)

We source none of the preparations named on this page — not the injectable copper peptide, not the branded blends. Each fails the statutory test, and we do not arrange what a pharmacy cannot lawfully make. This reflects our commitment to legally compliant sourcing coordination and protection of our clinic partners from enforcement risk.

We maintain this page because clinics are being told otherwise. What we can do instead — establishing current status by route, assessing a blend’s component list, testing supplier representations against the primary record, and building a compliance file — is set out in our guide to the compounding framework.

If FDA opens a rulemaking or alters the nominations list in a way that affects these substances, we will update this page within five business days of the notice.

Sourcing Coordination & Inquiry Notice:

Phoenix Meds Inc. operates as a compliance-focused liaison for licensed healthcare facilities. Because GHK-Cu injectable, BPC-157, KLOW, and multi-peptide blends currently lack recognized compounding pathways under FDA Sections 503A/503B, our platform does not offer direct sales or unauthorized fulfillment. Licensed practitioners evaluating these research categories may access our coordination directory below to review state-specific regulatory statuses, verify vendor credentials, or request legal compliance packets.

Verify This Yourself

FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated 14 May 2026 — the GHK-Cu Category 1 entry and its injectable carve-out

Orrick — the April 2026 removals and the planned PCAC consultation on GHK-Cu

21 CFR 216.23 — the 503A Bulks List: six substances, no peptides

FDA — 503B Bulk Drug Substances List — five substances, no peptides

FDA — PCAC meeting, 23–24 July 2026 — the BPC-157, KPV and TB-500 reviews and their nominated uses

Related Clinic Resources

Choosing a Reliable Injectable Supplier
Vetting framework for any injectable supplier, with emphasis on statutory criteria and documentation.

Legal & Regulatory Status Overview
The statutory framework, criteria under 503A and 503B, enforcement risk and supplier due diligence across every category.

Medical Supply Chain Compliance
Documentation requirements, supplier vetting and regulatory due diligence across all therapeutic categories.

Storage and Handling of Lyophilized Peptides
Maintaining peptide integrity from arrival through reconstitution and administration.

Gut Health & Inflammatory Peptides
BPC-157 and KPV: FDA status, statutory criteria and supplier verification.

Injury Recovery & Tissue Repair
BPC-157 and TB-500 for acute injury and post-surgical recovery, with current regulatory position.

Disclaimer & Legal Status:

This page is educational and regulatory-tracking information for licensed clinics. It is not medical or legal advice. For current FDA regulatory status, legal compounding authority, and required due diligence, consult our complete Legal & Regulatory Status Overview and work with qualified legal counsel in your state.

Aesthetic peptide protocols:

As of August, 2026, no lawful compounding pathway exists under section 503A or 503B for GHK-Cu injectable, Fountain of Youth (FOY), or multi-peptide aesthetic combinations. Any clinic considering these protocols must verify current FDA guidance, consult qualified legal counsel, establish clear informed consent processes explaining the research-use status and limited human efficacy data, maintain detailed protocol documentation with objective measurements, and source only through properly licensed pharmacies and wholesalers—if sourcing is determined to be lawful by counsel.

Phoenix Meds Inc. operates as a sourcing coordinator only:

We are not physicians, pharmacists, dermatologists, or legal counsel. Nothing on this page constitutes an offer to source peptides without lawful compounding pathways. Phoenix Meds protects its clinic partners from compliance risk by declining to coordinate sourcing of peptides without established legal status. All clinical and sourcing decisions must be made by licensed practitioners in consultation with qualified legal counsel.